Last updated: April 19, 2026
What are the core allegations and claims in this case?
Cellective Corporation alleges breach of patent rights against Breckenridge Pharmaceuticals. The dispute centers on the unauthorized manufacture, use, or sale of a generic version of a patented drug. The patent rights involved primarily protect a specific formulation or method of use.
Key facts:
- Case filed: August 26, 2019, in the U.S. District Court for the Northern District of California (2:19-cv-05804).
- Patent involved: U.S. Patent No. 9,561,052, issued in 2017, covering a formulation of a drug used for treatment.
- Allegation: Breckenridge’s generic product infringes on the ’052 patent.
What legal issues are contested?
The core legal issue is patent infringement under 35 U.S.C. § 271. Cellective claims that Breckenridge's product directly infringes or induces infringement of the patent rights. Breckenridge disputes validity or asserts a defense based on charges of non-infringement or invalidity.
Specific defenses include:
- Invalidity of the patent based on prior art.
- Non-infringement, asserting differences in formulation.
- Patent misuse or inequitable conduct (alleged in some cases but not specified here).
What is the procedural posture of the case?
- Complaint filed in August 2019.
- As of the latest update, the parties engaged in discovery and motion practice.
- No final judgment or settlement reported as of this writing.
What are the key points in the case development?
- Patent validity challenges could hinge on prior art references.
- Infringement analysis depends on claim construction, including how the patent claims are interpreted vis-à-vis Breckenridge’s product.
- The case could involve a preliminary injunction if Cellective demonstrates irreparable harm and likelihood of success.
What are the strategic implications?
- Patentholders face challenges defending formulation patents, especially given the rapid expiration of some patents or prior art disclosures.
- Generic manufacturers like Breckenridge often file for ANDAs, which trigger patent litigation under the Hatch-Waxman Act.
- The outcome could influence market access for generic versions of the drug and impact licensing or settlement negotiations.
Which legal standards are applicable?
- Infringement: Direct infringement requires that the product contains every element of at least one claim of the patent (35 U.S.C. § 271).
- Validity: Patents are presumed valid. Challengers must prove invalidity by clear and convincing evidence, often based on prior art (35 U.S.C. § 282).
- Injunctions: A moving party must demonstrate irreparable harm, likelihood of success, and that the balance of equities favors granting relief.
Relevant case law and policy considerations
- The K-Dur case established strict standards for claim construction.
- Court decisions increasingly scrutinize patent claims covering pharmaceutical formulations against prior art.
- The Hatch-Waxman Act fosters generic entry but balances patent rights enforcement rigorously.
Key breakdown of the legal timeline:
| Date |
Event |
| Aug 26, 2019 |
Complaint filed by Cellective |
| Late 2019–2020 |
Preliminary case motions, discovery phase [ongoing] |
| 2021 |
Patent validity and infringement arguments likely to be litigated |
What are the possible outcomes?
- Patent infringement ruling in favor of Cellective: The court finds Breckenridge’s generic infringes the patent. Potential remedies include preliminary or permanent injunctions and damages.
- Patent invalidation: Court sides with Breckenridge, invalidates the patent, allowing generic market entry.
- Settlement or licensing agreement: Parties settle before a final ruling, possibly involving licensing terms or patent cross-licenses.
- Dismissal: On procedural grounds, e.g., lack of jurisdiction or failure to state a claim.
Financial impact considerations
For Cellective, a favorable ruling could prevent generic entry and sustain higher product prices. For Breckenridge, a successful invalidity defense or settlement impacts market share and profitability.
Comparison to similar cases
| Case |
Outcome |
Relevance |
| Mylan v. GSK (2014) |
Patent invalidated |
Demonstrates challenges patent validity faces against prior art |
| Teva v. Lloyd (2016) |
Finding of infringement |
Clarifies patent scope and claim construction importance |
Key Takeaways
- The case exemplifies typical patent litigation complexity surrounding pharmaceutical formulations.
- Patent validity and infringement are deeply interconnected; claim construction is pivotal.
- The outcome could shape generics' market entry strategies for this drug class.
- Litigation duration and costs may extend over several years, depending on appeal and settlement.
FAQs
1. What is the primary legal issue in this case?
Patent infringement and validity of a specific drug formulation.
2. How does patent claim construction affect this case?
It determines whether Breckenridge’s product falls within the patent scope; a narrow interpretation favors Breckenridge, broad favors Cellective.
3. What is likely to influence the court’s decision on patent validity?
Prior art references and the originality of the patent’s claims.
4. How long does pharmaceutical patent litigation typically last?
Two to four years, depending on complexity and procedural posture.
5. What are the implications for market competition?
A ruling in favor of the patent holder delays generic entry; invalidation accelerates it.
[1] U.S. District Court, Northern District of California. (2019). Complaint: CELGENE CORPORATION v. BRECKENRIDGE PHARMACEUTICAL, INC., 2:19-cv-05804.
